DNTH - Company ID 0001690585
Dianthus Therapeutics, Inc. /DE/ trades as DNTH and has a market capitalization of $5.47 B, making it the #1354 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $2.04M, down 67.3% from the prior year and net income of -$162.34M. This page tracks Dianthus Therapeutics, Inc. /DE/ through 624 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin compressed from -888.1% to -7973.3% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Major company event | 8-K | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Dianthus Therapeutics
Dianthus Therapeutics to Participate in Two Investor Conferences | Dianthus Therapeutics
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results | Dianthus Therapeutics
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Dianthus Therapeutics
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Dianthus Therapeutics
The largest companies sharing Dianthus Therapeutics, Inc. /DE/'s SEC industry classification (pharmaceutical preparations).
Dianthus Therapeutics, Inc. /DE/ (DNTH) has a market capitalization of $5.47 B as of 2026-07-09, ranking #1354 among US-listed companies.
Dianthus Therapeutics, Inc. /DE/ reported revenue of $2.04M for fiscal year 2025, a decrease of 67.3% year over year.
In its latest fiscal year Dianthus Therapeutics, Inc. /DE/ reported a net loss of $162.34M.